" "@en . . "approved"@en . . . "The half-life after an intravenous dose is 41 to 59 minutes. "@en . "Approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations. Cefoxitin passes into pleural and joint fluids and is detectable in antibacterial concentrations in bile."@en . "(6R,7S)-3-[(Carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"@en . . "Pandurang Deshpande, Bhausaheb Khadangale, \"Process for the preparation of cefoxitin.\" U.S. Patent US20060252928, issued November 09, 2006."@en . . "Cefoxitine"@en . "35607-66-0"@en . . . . . . . . "Cefoxitina"@en . . . . . . "Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans."@en . . . . . . . "The bactericidal action of cefoxitin results from inhibition of cell wall synthesis."@en . . . . . . "CFX"@en . . . "Cephoxitin"@en . . . . . . . "The acute intravenous LD50 in the adult female mouse and rabbit was about 8.0 g/kg and greater than 1.0 g/kg, respectively. The acute intraperitoneal LD50 in the adult rat was greater than 10.0 g/kg."@en . . . . . "Cefoxitinum"@en . "Cefoxitin"@en . . . . . . . "Enteric bacteria and other eubacteria"@en . . . . . "For the treatment of serious infections caused by susceptible strains microorganisms."@en . . . . . . . . . . . . . . . "Rephoxitin"@en . . . . . . . . . . . . "Ceftoxitin"@en . "Cefoxitin"@en . . .